Objectives: The purpose of this project is to develop a decision model of the detection and treatment of breast cancer. The model will use patient- assessed utilities (when they are available) concerning benefits and side effects or morbidity of the various therapeutic and information-gathering procedures. When utilities are not available the model will focus on duration of survival and default utilities. The model will also incorporate medical costs. Therapeutic and other decisions occurring early in the course of the disease assume that subsequent decisions are optimal for that patient's circumstances and with respect to her utilities. The overall objectives of this project are to (i) Improve patient care and quality of advice given to patients by providing oncologists with a tool for helping them choose interventions, and (ii) Provide a mechanism for evaluating the usefulness of current and proposed interventions, and also of research programs in breast cancer.
Specific Aims : l. Develop a decision model and interactive computer software tailored to individual patient characteristics and utilities (when available). The model will use probability distributions of outcomes based on literature reviews and metaanalyses. Default utilities will be based on the assessments of a panel of breast cancer physicians and nurses. 2. Develop instruments for assessing patient utilities at various time points in the disease. These will be available for use by clinicians as part of the interactive software and will help tailor therapy to an individual patient's characteristics and preferences. 3. Adapt the model to produce cost estimates of the various options. 4. Adapt the model to allow for its use in evaluating the utility of a new intervention or research program. Methods: Choice from among preventive or therapeutic strategies depends on options available in the future. The model developed will consider future options and their possible outcomes explicitly. Namely, the optimization algorithm will proceed backwards in time (that is, using dynamic programming). The approach is to consider the end of the disease cycle first. Using patient utilities of outcomes, the model will evaluate the expected utilities of the various metastatic settings. Each such setting has a probability of occurring depending on the interventions taken in the immediately preceding decision opportunity. Finding these probabilities allows for finding the expected utility of each possible intervention in the previous period by averaging outcome utilities in the current period with respect to the probabilities. Proceeding backwards in time-accruing costs and benefits in the process-leads to the early clinical and preclinical stages of the disease. In the process, each intervention and prevention strategy can be evaluated depending on an individual's characteristics and utilities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA068438-02
Application #
5209483
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Osada, Takuya; Hartman, Zachary C; Wei, Junping et al. (2018) Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. Breast Cancer Res 20:90
Goncalves, Rodrigo; DeSchryver, Katherine; Ma, Cynthia et al. (2017) Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. Breast Cancer Res Treat 165:355-364
Mertins, Philipp; Yang, Feng; Liu, Tao et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13:1690-704
Li, Shunqiang; Shen, Dong; Shao, Jieya et al. (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4:1116-30
Cao, Yiting; Eble, Joseph M; Moon, Ejung et al. (2013) Tumor cells upregulate normoxic HIF-1? in response to doxorubicin. Cancer Res 73:6230-42
Ellis, Matthew J; Ding, Li; Shen, Dong et al. (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486:353-60
D'Amato, Nicholas C; Ostrander, Julie H; Bowie, Michelle L et al. (2012) Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system. PLoS One 7:e45684
Aird, Katherine M; Allensworth, Jennifer L; Batinic-Haberle, Ines et al. (2012) ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res Treat 132:109-19
Il'yasova, Dora; Kennedy, Kelly; Spasojevic, Ivan et al. (2011) Individual responses to chemotherapy-induced oxidative stress. Breast Cancer Res Treat 125:583-9
Ye, Xiaodong; Fels, Diane; Tovmasyan, Artak et al. (2011) Cytotoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate. Free Radic Res 45:1289-306

Showing the most recent 10 out of 103 publications